Immunovant IMVT
NASDAQ IMVT
$36.28 +0.57 (+1.60%)
As of: Nov 11, 2026 · 9:52 AM EST

Immunovant (IMVT) Non-Current Deferred Revenue (2019)

Updated

Immunovant (IMVT) reported Non-Current Deferred Revenue of $4.03 million for fiscal Q2 2020 (quarter ended Sep 30, 2019), unchanged from the prior quarter.

Analysis

Immunovant (IMVT) Non-Current Deferred Revenue (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Immunovant 7.38 Bn 3.97 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 4.03 Mn
Jun 30, 2019 4.03 Mn
API Access

Immunovant Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=IMVT&period=max&api_key=YOUR_API_KEY